secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003854
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam prelim 2023 product rev $1.24B (+39% YoY); Q4 growth across all drugs
-----------------------------------------------------------------------------

- Full-year 2023 global net product revenues $1,241M, up 39% YoY (39% constant currency).
- Q4 2023 revenues: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.
- Year-end cash & investments ~$2.4B, up from $2.2B at end of 2022.
- Over 4,060 patients on ONPATTRO/AMVUTTRA; over 650 on GIVLAARI, over 430 on OXLUMO at year-end 2023.
- Management cites strong patient demand and commercial execution; HELIOS-B readout expected early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/0001193125-24-003854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer